# Drugs Susceptibility Testing in Leprosy Patients from Côte d'Ivoire Reveals Multidrugs Resistance Combination Cases to Dapsone, Rifampicin and Ofloxacin

David Coulibaly N'golo, Roger Dehe Bahou, Solange Kakou-N'gazoa, Henry Kouakou, Christiane Amon Aby, Aboubacar Sylla, Alain Dit Philippe Bidie, Vagamon Bamba, Mireille Dosso

► To cite this version:

David Coulibaly N'golo, Roger Dehe Bahou, Solange Kakou-N'gazoa, Henry Kouakou, Christiane Amon Aby, et al. Drugs Susceptibility Testing in Leprosy Patients from Côte d'Ivoire Reveals Multidrugs Resistance Combination Cases to Dapsone, Rifampicin and Ofloxacin. American journal of microbiological research, 2020, 8 (4), pp.160-163. 10.12691/ajmr-8-4-6. pasteur-03997227

HAL Id: pasteur-03997227

https://riip.hal.science/pasteur-03997227

Submitted on 20 Feb 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Drugs Susceptibility Testing in Leprosy Patients from Côte d'Ivoire Reveals Multidrugs Resistance Combination Cases to Dapsone, Rifampicin and Ofloxacin

Coulibaly N'Golo David<fnref n="1" />,*, Dehe Bahou Roger<fnref n="1" />,<fnref n="2" />, Kakou-N'Gazoa Solange<fnref n="1" />, Kouakou henry<fnref n="3" />, Amon Aby Christiane<fnref n="1" />,<fnref n="2" />, Sylla Aboubacar<fnref n="1" />, Bidie Alain Dit Philippe<fnref n="2" />, Bamba Vagamon<fnref n="3" />, Dosso Mireille<fnref n="1" />

Received November 15, 2020; Revised December 16, 2020; Accepted December 23, 2020

**Abstract** Leprosy is a chronic tropical infectious skin disease caused by an obligate intracellular pathogen called Mycobacterium leprae. Until now no vaccine was available so early diagnosis and treatment were the basic strategy for leprosy control. The treatment is based on combined drug therapy including Dapsone, Rifampicin, and Ofloxacin according protocols recommended by the WHO. However, anti-leprosy drugs resistance has been reported in several leprosy endemic region. The drug susceptibility testing was done by detecting mutation after sequencing of the drug resistance determining region. Côte d'Ivoire like many African countries has reaching the threshold of elimination of the disease and the PCT is available nationwide. On the basis of recurrences of therapeutic failures that could be due to misobservance of patients drug therapy or eventually due to circulating resistant strains, we evaluated the drug susceptibility in 155 patients from a leprosy care center in Côte d'Ivoire. Patients were previously diagnosed by clinicians and confirmed by PCR then the genetic drug susceptibility was done by PCR-direct sequencing of the drug resistance determining region of rifampicin, dapsone and ofloxacin used in the treatment. Our results showed multiple cases of multiresistance to anti-leprosy drugs in Côte d'Ivoire. This should be an alert for antibiotic resistance observatories, and policies so that more active surveillance was carried out for the control and surveillance of *M. leprae* resistance to drugs.

**Keywords:** leprosy, *M. leprae*, multidrug resistance, Côte d'Ivoire

**Cite This Article:** Coulibaly N'Golo David, Dehe Bahou Roger, Kakou-N'Gazoa Solange, Kouakou henry, Amon Aby Christiane, Sylla Aboubacar, Bidie Alain Dit Philippe, Bamba Vagamon, and Dosso Mireille, "Drugs Susceptibility Testing in Leprosy Patients from Côte d'Ivoire Reveals Multidrugs Resistance Combination Cases to Dapsone, Rifampicin and Ofloxacin." *American Journal of Microbiological Research*, vol. 8, no. 4 (2020): 160-163. doi: 10.12691/ajmr-8-4-6.

## 1. Introduction

Leprosy is a chronic tropical infectious disease caused by an obligate intracellular pathogen called *Mycobacterium leprae* (*M. leprae*). The infection results in disfigurement, exclusion from society and, often, in or from poverty. Despite the efforts of the WHO to eradicate the disease, the transmission chain was not interrupted. 208 619 new leprosy cases were registered globally in 2018, according to official figures from 159 countries from the six (06) WHO Regions.

Until now no vaccine was available so early diagnosis and treatment was the basic strategy for leprosy control. The diagnostic is generally based on clinicals but the complexity of clinical presentation with other skin disease

has hindered the development of molecular test to confirm cases. Concerning the treatment, it is based on combined drug therapy (MDT) including in first line Dapsone, Rifampicin, and clofazimine, and in second-line Ofloxacin, Minocyclin and Clarithromicin as recommended by the WHO [1,2]. However, the resistance of *M. leprae* to anti-leprosy drugs has been reported in several leprosy endemic region [3,4]. The drug susceptibility testing was done either by the mouse footpad method [5] which is cumbersome and time-consuming or by detecting mutation after direct sequencing of the drug resistance determining region (DRDR) [6]. Studies on anti-leprosy drug susceptibility testing had shown that drug resistance can occur either by transmission of a strain resistant (primary resistance) or most often by mutation of the wildtype drug-susceptible strain during therapy [7]. Côte d'Ivoire like many African countries has reaching the

<footnote n="1">¹Molecular Biology Platform, Pasteur Institute of Côte d'Ivoire, Route de dabou Km17, 01 BP 490 Abidjan, Côte d'Ivoire</footnote>

<footnote n="2">²UFR Biosciences, Laboratory of Pharmacodynamics Biochemistry, Felix Houphouët-Boigny University, Abidjan, Côte d'Ivoire</footnote>

<footnote n="3">³Follereau Raoul Institute, Adzopé, Côte d'Ivoire</footnote>

<footnote>*Corresponding author: davidcoulibalyngolo@pasteur.ci; david79tr@yahoo.fr</footnote>
threshold of elimination of the disease and the PCT is
available nationwide. The diagnosis of leprosy in Côte
d'Ivoire is essentially clinical and microbiological
approaches were restricted to microscopy. On the basis of
recurrences of therapeutic failures that could be due to
misobservance of patient drug therapy or eventually due to
circulated resistant strains, we evaluated the drug
susceptibility in some patients from a leprosy care center.
No study on leprosy drugs susceptibility was until now
done in Côte d'Ivoire.

**2. Materials and Methods**

**2.1. Study Population**

155 patients were enrolled for this study. All patients
were diagnosed suspected cases of leprosy by clinicians of
the Raoul Follereau Institute of Côte d'Ivoire, a treatment
center for leprosy in the south area of Côte d'Ivoire.
Molecular analyses were done at the Pasteur institute of
Côte d'Ivoire.

**2.2. Ethics Statement**

This study was approved by the National Ethic
committee for research of Côte d'Ivoire: "Comité National
d'Ethique de la Recherche de Côte d'Ivoire (CNER)"
under the approval number N/Réf: N°140/MSHP/CNER-km.
All participants approved the research protocol and signed
the informed consent after read of the study information
notice.

**2.3. Biological Samples**

The biological samples to be analyzed consisted of
nasal swabs and dermal pulp fluid in each patient
clinically diagnosed for leprosy. Dermal pulp fluid was
collected from each right and left earlobe when possible.

For microscopy, smears were performed from a nasal
swab and dermal pulp fluid while for the molecular
analyzes, the nasal swab and the dermal pulp fluid were
recovered in a 2 ml microtubes containing 500 µl of
phosphate buffered saline (PBS).

**2.4. DNA Extraction and Molecular Cases**
**Confirmation**

DNA was extracted from samples using a modified
guanidinium thiocyanate protocol described by
Chomczinski P et al. [8]. Briefly 300 µl of each samples
were pre-treated by boiling at 95°C for thirty minutes then
DNA was extracted with a lysis buffer containing 5M
guanidine thiocyanate, 50 mM Tris, pH = 8.0, 10mM
EDTA, 5% 2-mercaptoethanol, 2% Triton X-100. After
centrifugation the lysate was transferred into a sterile 1.5
mL Eppendorf tubes and DNA was precipitated with
isopropanol and sodium acetate (3M). The DNA was
then washed with absolute ethanol (96%) and finally
resuspended with 150 µl of Tris -EDTA (TE).

Leprosy cases were confirmed by conventional PCR
targeting the *Mycobacterium leprae* repetitive element
RLEP as described by Woods and Cole [9]. PCR was

performed in a final volume of 25 µl containing 5µl of
DNA template, 3mM of MgCl2,0.4µM of each primers,
0.6 mM of dNTPs, 2X buffer and 0.04 U/µL of
polymerase.

PCR conditions were done in a GeneAmp 9700 PCR
System (Applied Biosystems) with the following program :
an initial denaturation at 94°C for 5min following by 35
cycles consisted of denaturation: 94°C for 30s, annealing:
57°C for 30s, extension: 72°C during 60s and a final
extension at 72°C for 10 min.

PCR products (545bp) were revealed using a GelDoc
EZ imager (BioRad) after an electrophoresis in a 2%
agarose gel containing SybrGreen.

**2.5. Sequencing and Molecular Drug Susceptibility Test**

Molecular drug susceptibility were performed only
on positive RLEP-PCR patients who presented a
bascilloscopic index superior or equal to +1. The level of
resistance were not evaluate. The presence of mutations in
the drug resistance determining regions (DRDR) of *RpoB*,
*folP1*, and *gyrA* genes associated with Rifampicin,
Dapsone, and Ofloxacin resistance, respectively were
tested using *M. leprae* DRDR primers as described by
Shinji Maeda et al. [10]. Each DRDR gene was amplified
separately and attended PCR products were purified and
sequences were obtained on a 24 capillary ABI 3500 XL
Genetic analyzer (Applied Biosystem).

Bioinformatics analysis were done using MEGA software
version 7.0 [11]; and for the mutations identification in the
DRDR genes, sequences were aligned to the *M. leprae*
Tamil Nadu (TN) reference strain sequence.

**3. Results and Discussion**

Of the 155 patients, 131/155 (85%) were tested positive for PCR RLEP. Among them 69 presented a bascilloscopic index greater than or equal to +1. They were distributed as follows: 52.90% of new cases, 28.39% of old cases and 18.71% of relapses cases. Thirty two out of the 69 (58,18%) analyzed patients were confirmed positive for the RLEP PCR using one of the nasal swab or dermal pulp fluid's type sample. Among the positive patients for the RLEP PCR, 26 of them had a null bascilloscopic index. These results show the interest of molecular diagnostic in confirming leprosy cases were traditional standard methods like microscopy or culture are limited. Effectively while the bascilloscopy has a poor detection limit (10⁴ bacilli) [12], *M. leprae* culture is difficult on axenic media and time consuming using mouse footpad assay [13].

Previously, the assessment of chemotherapy efficacy in
leprosy was difficult, since the only reliable method for
determining whether *M. leprae* was viable depended on its
growth on mouse footpads [14]; but today with new
molecular technics based on PCR, those were not useful
for follow-up of treatment, but for detection of drug
resistance [15,16]. So *rpoB*, *folp1* and *gyrA* remains the
main groups of *M. leprae* genes identified for their
correspondence to drug resistance [17,18].

The amplification of the DRDR for Rifampicin,
Dapsone and Ofloxacin as described by Shinji Maeda et al.
[10] showed the following results: 86.95% (60/69) of the patients amplified the *rpoB* gene associated with the rifampicin resistance (Figure 1) while 100% (69/69) of them amplified the *folp1* (Figure 2) gene associated with the dapsone resistance.

<figure><img src="image_2.png" /><figcaption>**Figure 1.** *rpoB* gene PCR amplification products (~305bp). Revelation was done on a 3% gel agarose electrophoresis. M: molecular weight marker; T+: Positive control; T-: Negative control(DNase/RNase free water); line 1 to 6: samples</figcaption></figure>

<figure><img src="image_3.png" /><figcaption>**Figure 2.** *folp1* gene PCR amplification products (~388bp). Revelation was done on a 3% gel agarose electrophoresis. M: molecular weight marker; T+: Positive control; T-: Negative control(DNase/RNase free water); line 1 to 6: samples</figcaption></figure>

For the DRDR related to the fluoroquinolone resistance (ofloxacin), 52 out of 69 (75.66%) amplified it (Figure 3).

<figure><img src="image_4.png" /><figcaption>**Figure 3.** *gyrA* gene PCR amplification products (~342bp). Revelation was done on a 3% gel agarose electrophoresis. M: molecular weight marker; T+: Positive control; T-: Negative control (DNase/RNase free water); line 1 to 8: samples</figcaption></figure>

48/69 samples amplified both of the *rpoB*, *folp1* and *gyrA* gene. The fact that all the samples had not amplified simultaneously both of the 3 genes conferring *M. leprae* drug resistance is probably due multiple alterations in *M. leprae* genome which composed of 70% pseudogenes [19]. Another reason could be due to a particularity of Ivoirian strains; unfortunately there is no study on Ivoirian *M. leprae* strains complete genome until now. Like Sekar B. *et al.* [20] suggested that the genetic detection of resistance has some inherited limitations such as resistance mechanisms not mediated by target gene

mutations cannot be detected, or the gene may be present but not necessarily translated.

All 48 samples were sequenced and the sequences were aligned with the sequence of the reference strain TN in order to identify the mutations.

For the *rpoB* gene: 24 out of the 48 patient sequences (50%) showed a wild-type profile identical to the sequence of the reference strain TN. In 24 patients sequences, mutations were detected, 11 of which (22.91%) defined missense mutations conferring resistance to rifampicin. The various missense mutations observed were at the position 438 (Gln→Val) (1/11); 441(Asp→Asn) (2/11); 456(Ser→Leu) (5/11); 456(Ser→Phe) (3/11) (Table 1).

<table><caption>**Table 1.** Drug resistance gene and observed mutations in Ivoirian patients</caption><thead><tr><th rowspan="2">Resistance gene</th><th rowspan="2">Wild type profile</th><th rowspan="2">Mutant profile</th><th colspan="3">Observed mutations</th></tr><tr><th>Position</th><th>Type</th><th>Number</th></tr></thead><tbody><tr><td rowspan="3">Folp1</td><td rowspan="3">20/48</td><td rowspan="3">28/48</td><td>53</td><td>Thr→Iso</td><td>10/28</td></tr><tr><td>55</td><td>Pro→Arg</td><td>11/28</td></tr><tr><td>55</td><td>Pro→Leu</td><td>7/28</td></tr><tr><td rowspan="4">rpoB</td><td rowspan="4">24/48</td><td rowspan="4">11/48</td><td>438</td><td>Gln→Val</td><td>1/11</td></tr><tr><td>441</td><td>Asp→Asn</td><td>2/11</td></tr><tr><td>456</td><td>Ser→Leu</td><td>5/11</td></tr><tr><td>456</td><td>Ser→Phe</td><td>3/11</td></tr><tr><td>gyrA</td><td>39/48</td><td>9/48</td><td>91</td><td>Ala→Val</td><td>9/9</td></tr></tbody></table>

For the *folp1* gene: 20 of the 48 patients had their sequence identical to that of the reference sequence TN while 28 presented a mutation conferring resistance to dapsone. The mutations observed in the *folp1* gene were varied: Thr53Iso (10/28); Pro55Arg (11/28); Pro55leu (07/28) (Table 2).

<table><caption>**Table 2.** PCT drugs resistance combination observed in Ivoirian patients</caption><thead><tr><th>Drug associations</th><th>Number of resistance cases observed</th></tr></thead><tbody><tr><td>Rifampin + Dapsone</td><td>8/48(16.66%)</td></tr><tr><td>Ofloxacin + Dapsone</td><td>4/48(8.33%)</td></tr><tr><td>Ofloxacin + rifampin</td><td>4/48(8.33%)</td></tr><tr><td>Rifampin + Dapsone + ofloxacin</td><td>3/48(6.25%)</td></tr></tbody></table>

As regards the *gyrA* gene involved in resistance to fluoroquinolone (Ofloxacin), in 9 out of 48 patients, Ala91Val-type mutations were observed.

In some patients, simultaneous search for mutations in the *RpoB*, *folp1* and *gyrA* genes has made it possible to observe cases of multi-resistance. Thus cases of dual resistance to: rifampicin / dapsone; ofloxacin / dapsone; ofloxacin / rifampicin were found with respective frequencies of 16.66% (8/48) and 8.33% (4/48) for the last two combinations.3 cases of triple resistance to the molecules used in multidrug therapy for the treatment of leprosy were also detected (Table 2).

In view of these results, it is not surprising to observe cases of genetic resistance to antibiotics used in the treatment of leprosy in Côte d'Ivoire. Indeed, many countries around the world have reported cases of resistance to multidrug therapy [13,18,21] and Africa does not have less spare [7]. Dehe *et al.* [22] were already presented cases of resistance to rifampicin in Côte d'Ivoire
but not to the various antibiotics used in MDT. The MDT for 12 or 24 months against *M. leprae* infection was usually started without information of drug resistance or in some cases without molecular confirmation of clinical cases; although some clinical aspects of leprosy remain obvious to experienced practitioners, today many skin diseases may be related to it.

On the other hand, no effort to monitor *M. leprae*'s resistance to MDT [23] was done by governments in low, middle-, and endemic countries. Effectively, even if molecular methods are becoming more feasible and affordable in many low-cost countries laboratories, there is no active drug resistance surveillance for leprosy control in Côte d'Ivoire. Practicians are limited to the efficacy of the treatment without take care that due to the lack of several crucial metabolic pathways in *M. leprae*, it's accurate diagnosis and also monitoring of patients during and after treatment is often complicated.

## 4. Conclusion

Although the finding of our study is not new for many leprosy endemic countries, it is a first report of its kind in west Africa region of multiple dual and triple resistance cases to anti-leprosy drugs. This should constitute an alert for antibiotic resistance observatories and Ivoirian's health politics. This work reinforce Who strategy in its global surveillance system to monitor the development of drug resistance in *M. leprae*.

## Acknowledgements

We thank Pasteur Institute of Cote d'Ivoire for the financial and technical support in the achievement of samples and lab tests. We are also grateful to the Raoul Follereau Institute of Côte d'Ivoire for having eased the access to their patients and for samples collection.

## Statement of Competing Interests

The authors have no competing interests.

## References

[1] World Health Organisation study group. *Chemotherapy of leprosy for control program*. WHO technical report series Geneva. 1982; 675: 1-36.

[2] World Health Organization. (1998). *Global leprosy distribution in 1998*. Weekly Epidemiological Record, 73 (25), 188-190.

[3] Kai M, Nguyen Phuc NH, Nguyen HA, Pham TH, Nguyen KH, Miyamoto Y, Maeda Y, Fukutomi Y, Nakata N, Matsuoka M, Makino M, Nguyen TT. *Analysis of drug-resistant strains of Mycobacterium leprae in an endemic area of Vietnam*. Clin Infect Dis. 2011 Mar 1; 52(5): e127-32.

[4] WHO/ Department of Control of Neglected Tropical Diseases (2009). *Global leprosy situation*, 2009 Weekly epidemiological record, 33(84), 333-340.

[5] Levy L, Ji B. *The mouse foot-pad technique for cultivation of Mycobacterium leprae*. Lepr Rev. 2006 Mar; 77(1): 5-24. Erratum in: Lepr Rev. 2006 Jun; 77(2): 170. PMID: 16715686.

[6] World Health Organisation: *A guide for antimicrobial resistance in leprosy* update 2017.

[7] Avanzi C, Busso P, Benjak A, Loiseau C, Fomba A, Doumbia G, Camara I, Lamou A, Sock G, Drame T, Kodio M, Sakho F, Sow S O, Cole S T, Johnson R C. *Transmission of Drug-Resistant Leprosy in Guinea-Conakry Detected Using Molecular Epidemiological Approaches*, Clinical Infectious Diseases, Volume 63, Issue 11, 1 December 2016, Pages 1482-1484.

[8] Chomczynski P and Sacchi N. (1987). *Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction*. Analytical Biochemistry. (162) 156-159.

[9] Woods SA, Cole ST. *A family of dispersed repeats in Mycobacterium leprae*. Mol Microbiol. 1990 Oct; 4(10): 1745-51.

[10] Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, Kimura H, Kobayashi K, Kashiwabara Y. *Multidrug resistant Mycobacterium leprae from patients with leprosy*. Antimicrob Agents Chemother. 2001 Dec; 45(12): 3635-9.

[11] Kumar S, Stecher G, Tamura K. MEGA7: *Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets*. MolBiolEvol. 2016 Jul; 33(7): 1870-4.

[12] Siwakoti S, Rai K, Bhattarai NR, Agarwal S, Khanal B. *Evaluation of Polymerase Chain Reaction (PCR) with Slit Skin Smear Examination (SSS) to Confirm Clinical Diagnosis of Leprosy in Eastern Nepal*. PLoSNegl Trop Dis. 2016 Dec 27; 10(12): e0005220.

[13] Izzaty Dalawi, Min Moon Tang, Amrish Shah Osman, Muhamad Ismail, Rehan Shuhada Abu Bakar, Jiloris F. Dony, Johari Zainol, AsmahJohar; *Drug resistance pattern of Mycobacterium leprae from mouse footpad cultivation between 1997 to 2013 in Malaysia*; Leprosy Review; 2017; 88; 4; 463-477.

[14] Jamil S, Keer JT, Lucas SB, Deckrell HM, Chiang TJ, Hussain R, Stoker NG 1993. *Use of the polymerase chain reaction to access efficacy of leprosy chemotherapy*. Lancet 342: 264-267.

[15] Sekar B, Arunagiri K, Kumar BN, Narayanan S, Menaka K, Oommen PK. *Detection of mutations in *folp1*, *rpoB* and *gyrA* genes of *M. leprae* by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy*. Lepr Rev. 2011 Mar; 82(1): 36-45. PMID: 21644470.

[16] Li W, Sakamuri RM, Lyons DE, Orcullo FM, Shinde V, Dela Pena EL, Maghanoy AA, Mallari IB, Tan EV, Nath I, Brennan PJ, Balagon M, Vissa V. *Transmission of dapsone-resistant leprosy detected by molecular epidemiological approaches*. Antimicrob Agents Chemother. 2011 Nov; 55(11): 5384-7.

[17] Williams DL, Gillis TP. *Molecular detection of drug resistance in Mycobacterium leprae*. Lepr Rev. 2004 Jun; 75(2): 118-30. PMID: 15282962.

[18] Matsuoka M. *Drug resistance in leprosy*. Jpn J Infect Dis. 2010 Jan; 63(1): 1-7. PMID: 20093754.

[19] Singh P, Cole ST. *Mycobacterium leprae: genes, pseudogenes and genetic diversity*. Future Microbiol. 2011 Jan; 6(1): 57-71.

[20] Sekar B, Arunagiri K, Kumar BN, Narayanan S, Menaka K, Oommen PK. *Detection of mutations in *folp1*, *rpoB* and *gyrA* genes of *M. leprae* by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy*. Lepr Rev. 2011 Mar; 82(1): 36-45. PMID: 21644470.

[21] Beltrán-Alzate, Camilo, Fernando López Díaz, M. Romero-Montoya, R. Sakamuri, Wei Li, M. Kimura, P. Brennan and N. Cardona-Castro. *Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country*. PLoS Neglected Tropical Diseases 10 (2016): n. pag.

[22] Dehe BR, Coulibaly ND, Amon AC, Sylla A, Kouakou H, Kakou-Ngazoa SE, Bidie Alain DP and Bamba V. *Molecular detection of mutations in *rpoB* gene involved in rifampicin resistance in leprosy patients in Côte d'Ivoire*. World Journal of Biology Pharmacy and Health Sciences, 2(1), 01-08.

[23] Moraes MO. *Editorial Commentary: Drug-Resistance in Leprosy: Moving Toward Understanding the Scope of the Problem and How to Tackle It*. Clin Infect Dis. 2016 Dec 1; 63(11): 1485-1486.

<figure><img src="image_5.png" /></figure>